Boehringer

Dr. Stefan Seemann is appointed President of PARI Pharma GmbH

Retrieved on: 
Tuesday, June 22, 2021
Boehringer Ingelheim, Seemann, Ingelheim am Rhein, Boehringer, Economy of Germany, Germany

STARNBERG, Germany, June 22, 2021 /PRNewswire/ --Dr. Stefan Seemann will replace Dr. Martin Knoch as President of PARI Pharma GmbH on July 1, 2021.

Key Points: 
  • STARNBERG, Germany, June 22, 2021 /PRNewswire/ --Dr. Stefan Seemann will replace Dr. Martin Knoch as President of PARI Pharma GmbH on July 1, 2021.
  • Long-time PARI executive Dr. Stefan Seemann has been chosen as his successor by top management.
  • After receiving a PhD in chemistry, Dr. Seemann worked in the production and development divisions of Boehringer Ingelheim for several years before joining PARI Pharma in 2000.
  • "The appointment of Stefan Seemann prioritizes continuity," explains Dr. Johann Zimmermann, CEO of the PARI corporate group.

Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks

Retrieved on: 
Wednesday, June 9, 2021
Infectious diseases, Boehringer Ingelheim, Emerging infectious disease, Ingelheim am Rhein, Boehringer, Economy of Germany, Germany, Health

Utilising the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow Boehringer Ingelheim's R&D efforts to be prioritised accordingly.

Key Points: 
  • Utilising the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow Boehringer Ingelheim's R&D efforts to be prioritised accordingly.
  • Researchers from both organisations will work side-by-side to combine real-world evidence and the latest AI algorithms to identify infectious disease outbreaks and respond accordingly.
  • Lifebit REAL uses advanced analytic capabilities to automatically notify users of relevant outbreaks, such as transboundary disease spread or the emergence of novel pathogens, such as COVID-19.
  • Dr. Eric Haaksma, Head of Animal Health Global Innovation Boehringer Ingelheim, shared: "External innovation is becoming an increasingly important aspect of our R&D playbook.

Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks

Retrieved on: 
Wednesday, June 9, 2021
Infectious diseases, Boehringer Ingelheim, Emerging infectious disease, Ingelheim am Rhein, Boehringer, Economy of Germany, Germany, Health

Utilising the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow Boehringer Ingelheim's R&D efforts to be prioritised accordingly.

Key Points: 
  • Utilising the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow Boehringer Ingelheim's R&D efforts to be prioritised accordingly.
  • Researchers from both organisations will work side-by-side to combine real-world evidence and the latest AI algorithms to identify infectious disease outbreaks and respond accordingly.
  • Lifebit REAL uses advanced analytic capabilities to automatically notify users of relevant outbreaks, such as transboundary disease spread or the emergence of novel pathogens, such as COVID-19.
  • Dr. Eric Haaksma, Head of Animal Health Global Innovation Boehringer Ingelheim, shared: "External innovation is becoming an increasingly important aspect of our R&D playbook.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Retrieved on: 
Wednesday, June 2, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Peptide hormones, Hormones, Boehringer Ingelheim, Fast track, Glucagon, Endocrine system, Boehringer, Organ systems

20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).
  • The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need.
  • Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.
  • Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH, said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Retrieved on: 
Wednesday, June 2, 2021
Boehringer Ingelheim, Zealand Pharma, Boehringer, Glucagon-like peptide-1, Economy of Germany, Companies, Health care

Ingelheim, Germany and Copenhagen, Denmark, 2 June, 2021 Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Ingelheim, Germany and Copenhagen, Denmark, 2 June, 2021 Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).
  • Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.
  • Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH, said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma.

Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement

Retrieved on: 
Monday, May 24, 2021
Health, Genetics, General Health, Research, Pharmaceutical, Science, Boehringer Ingelheim, Branches of biology, Boehringer, Ingelheim am Rhein, RNA interference, Biology, Economy of Germany, Nonalcoholic Steatohepatitis (NASH), RNAi and Dicerna’s GalXC, Dicerna Pharmaceuticals, Inc., NONALCOHOLIC STEATOHEPATITIS (NASH), RNAI AND DICERNA’S GALXC, DICERNA PHARMACEUTICALS, INC.

Acceptance of DCR-LIV2 as a development candidate triggered a single-digit multimillion USD preclinical milestone payment to Dicerna, which the Company expects to receive in the second quarter of 2021.

Key Points: 
  • Acceptance of DCR-LIV2 as a development candidate triggered a single-digit multimillion USD preclinical milestone payment to Dicerna, which the Company expects to receive in the second quarter of 2021.
  • Under the terms of the existing agreement between Dicerna and Boehringer Ingelheim, Dicerna is eligible to receive up to $170.0 million in potential additional development and commercial milestones related to DCR-LIV2.
  • Rather than seeking to inhibit a protein directly, the RNAi approach can prevent a disease-causing proteins creation, directly impacting disease manifestation.
  • Examples of forward-looking statements include, among others, statements we make regarding the collaboration agreement with Boehringer Ingelheim International GmbH and the therapeutic potential of the development candidate under such collaboration.

Boehringer Ingelheim's Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation

Retrieved on: 
Monday, May 24, 2021
Solute carrier family, Glycine reuptake inhibitors, Branches of biology, Membrane biology, Schizophrenia, BI 425809, Nootropics, Boehringer Ingelheim, Sodium- and chloride-dependent glycine transporter 1, Glycine transporter, Boehringer

RIDGEFIELD, Conn., May 24, 2021 /PRNewswire/ -- Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).

Key Points: 
  • RIDGEFIELD, Conn., May 24, 2021 /PRNewswire/ -- Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for BI 425809 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).
  • BI 425809, a novel glycine transporter-1 (GlyT1) inhibitor, forms a key component of Boehringer Ingelheim's Mental Health research program.
  • Central to many everyday tasks, impairment of cognitive function is a major burden for people with schizophrenia, and no pharmacological treatments are currently approved for CIAS[2].
  • "This Breakthrough Therapy Designation further highlights the urgent need for novel treatments for people living with schizophrenia.

Covetrus Appoints Paul Fonteyne to its Board of Directors

Retrieved on: 
Tuesday, May 18, 2021
Consumer, Health, Pets, Veterinary, Pharmaceutical, Boehringer Ingelheim, Boehringer, XC2, Ingelheim am Rhein, Germany

b'Covetrus\xc2\xae (NASDAQ: CVET), a global leader in animal-health technology and services, announced the appointment of Paul Fonteyne to its Board of Directors, bringing the number of directors to eleven.

Key Points: 
  • b'Covetrus\xc2\xae (NASDAQ: CVET), a global leader in animal-health technology and services, announced the appointment of Paul Fonteyne to its Board of Directors, bringing the number of directors to eleven.
  • Mr. Fonteyne was with Boehringer-Ingelheim for 15 years in leadership roles, including serving as U.S. President and CEO.
  • \xe2\x80\x9cI am excited to join the board and add my perspective and experience to help drive Covetrus\xe2\x80\x99 transformation into a global leader in veterinary healthcare solutions.\xe2\x80\x9d\nMr.
  • Covetrus is headquartered in Portland, Maine with more than 5,500 employees serving over 100,000 customers around the globe.

Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners

Retrieved on: 
Tuesday, May 11, 2021
Articles, Ethics, Boehringer Ingelheim, Boehringer, Corporate social responsibility, WE, Ingelheim am Rhein

"Our hope is that through these collective donations to our nonprofit partners, we will help make stronger and healthier communities where we live and work.

Key Points: 
  • "Our hope is that through these collective donations to our nonprofit partners, we will help make stronger and healthier communities where we live and work.
  • Since its founding in 1885, Boehringer Ingelheim is independent and family-owned.
  • In 2020, Boehringer Ingelheim achieved net sales of around 22.33 billion USD (19.57 billion EUR).
  • Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.\nFor more information, please visit www.boehringer-ingelheim.us , or follow us on Twitter @BoehringerUS.\n'

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Retrieved on: 
Monday, May 10, 2021
Education, Health, Research, Science, Pharmaceutical, University, Biotechnology, Boehringer, Ingelheim am Rhein, BI, Germany

b'Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.\nPost-doctoral researchers awarded a three-year fellowship will have access to Yale\xe2\x80\x99s robust computational resources, biomedical data repositories and faculty expertise.

Key Points: 
  • b'Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.\nPost-doctoral researchers awarded a three-year fellowship will have access to Yale\xe2\x80\x99s robust computational resources, biomedical data repositories and faculty expertise.
  • If approved for a fellowship, they will be jointly mentored throughout the research process by industry experts and scientists from Boehringer Ingelheim \xe2\x80\x94 one of the world\xe2\x80\x99s leading pharmaceutical companies \xe2\x80\x94 as well as Yale\xe2\x80\x99s world-class researchers and scholars.
  • The center is an essential part of a growing data science hub at Yale University, which has identified integrated data science as one of its primary investment areas over the next decade.
  • It is part of a comprehensive strategic program at Boehringer Ingelheim which will harness the power of data science to transform drug discovery and development.